Provided by Tiger Trade Technology Pte. Ltd.

Clearmind Medicine, Inc.

1.35
-0.1000-6.90%
Post-market: 1.30-0.0500-3.70%19:59 EST
Volume:7.29M
Turnover:12.45M
Market Cap:2.02M
PE:-0.04
High:1.59
Open:1.48
Low:1.31
Close:1.45
52wk High:58.00
52wk Low:1.31
Shares:1.50M
Float Shares:1.25M
Volume Ratio:92.62
T/O Rate:583.87%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-30.3500
EPS(LYR):-67.7994
ROE:-179.39%
ROA:-53.11%
PB:1.70
PE(LYR):-0.02

Loading ...

BRIEF-Clearmind Medicine Enters Development Agreement For Intranasal Formulation Of Proprietary Nonhallucinogenic Neuroplastogen MEAI

Reuters
·
Feb 06

BUZZ-Polyrizon jumps as it teams up with Clearmind for intranasal drug delivery

Reuters
·
Feb 06

Clearmind Medicine Enters Into Development Agreement to Advance Intranasal Formulation for Its Proprietary Non-Hallucinogenic Neuroplastogen Meai

THOMSON REUTERS
·
Feb 06

Polyrizon Partners with Clearmind to Develop Intranasal MEAI Formulation

Reuters
·
Feb 06

Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation

THOMSON REUTERS
·
Feb 06

Clearmind Medicine Issues $2.5 Million in Convertible Promissory Notes

Reuters
·
Feb 05

Clearmind Medicine gibt Ausgabe von Wandelanleihen im Gesamtwert von 2,5 Millionen US-Dollar bekannt

Reuters
·
Feb 05

Clearmind Medicine welcomes inclusion of MEAI in bipartisan legislation

TIPRANKS
·
Feb 03

Clearmind Medicine erzielt Durchbruch mit MEAI in US-Gesetz für innovative Veteranen-Therapien

Reuters
·
Feb 03

Psychedelic: Clearmind completes second cohort treatment for CMND-100 trial

TIPRANKS
·
Jan 15

BRIEF-Clearmind Medicine Inc - Topline Results From Second Cohort Of CMND-100 Expected In Coming Months

Reuters
·
Jan 14

Clearmind Medicine Inc - Topline Results From Second Cohort of Cmnd-100 Expected in Coming Months

THOMSON REUTERS
·
Jan 14

Clearmind Medicine Completes Second Cohort Treatment in Phase I/IIa Trial for Alcohol Use Disorder Drug

Reuters
·
Jan 14

Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Trial for CMND-100

GlobeNewswire
·
Jan 14

Clearmind Medicine Says Nasdaq Compliance Regained on Minimum Bid Price Rule

MT Newswires Live
·
Dec 31, 2025

Clearmind Medicine Regains Compliance With Nasdaq Minimum Bid Price Requirement

THOMSON REUTERS
·
Dec 31, 2025

Clearmind Medicine Reports Positive Phase I/IIa Results for CMND-100 in Alcohol Use Disorder Trial

Reuters
·
Dec 29, 2025

Clearmind Medicine Advances Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder

Reuters
·
Dec 24, 2025

Clearmind Medicine Completes Second Cohort Enrollment in Phase I/IIa Trial for Alcohol Use Disorder Drug

Reuters
·
Dec 16, 2025

Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100

GlobeNewswire
·
Dec 16, 2025